^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD34 positive

i
Other names: CD34, CD34 Molecule, CD34 Antigen, Hematopoietic Progenitor Cell Antigen CD34
Entrez ID:
Related biomarkers:
24d
MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio. (PubMed, Leuk Res)
Using double-labeling for Bcl-2 and Ki-67 it could be shown that besides blast cells with a mutually exclusive Ki-67 and Bcl-2 expression, also blast cells concurrently exhibiting anti-apoptotic and proliferative marker expression were found. Integrating these two dynamic markers into MDS and AML diagnostic workups may enable informed conclusions about their biological behavior, facilitating individualized therapy decisions for patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule)
|
BCL2 expression • CD34 positive
27d
Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia. (PubMed, Eur Rev Med Pharmacol Sci)
A higher positive rate of bone marrow CD34 expression in children with B-ALL is associated with a favorable prognosis. Children with negative CD34 expression are relatively more prone to MRD and tumor relapse after chemotherapy.
Retrospective data • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PBX1 (PBX Homeobox 1) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • ANPEP (Alanyl Aminopeptidase, Membrane)
|
CD34 positive • MLL-AF4 fusion
1m
Hepatic hemangioma in a simple liver cyst mimicking biliary cystic neoplasm. (PubMed, Surg Case Rep)
Cavernous hemangiomas mimicking well-enhanced mural nodules can arise from simple liver cysts. In less malignant cases, laparoscopic biopsy or percutaneous targeted biopsy of the mural nodules, together with needle ablation, may be recommended to avoid unnecessary surgery.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD34 positive
1m
Mesenchymal skin tumors - Novel entities in the 5th edition of WHO classification of skin tumors. (PubMed, Cesk Patol)
In addition, EWSR1::SMAD3-rearranged fibroblastic tumors, superficial CD34-positive fibroblastic tumors, and NTRK-rearranged spindle cell neoplasms were newly included. Of the other changes, only the most important ones will be briefly mentioned.
Review • Journal
|
EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • NTRK (Neurotrophic receptor tyrosine kinase) • CREM (CAMP Responsive Element Modulator) • MITF (Melanocyte Inducing Transcription Factor) • CRTC1 (CREB Regulated Transcription Coactivator 1) • SMAD3 (SMAD Family Member 3)
|
CD34 positive
1m
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality. (PubMed, Transfusion)
We found no difference in survival, relapse, or GVHD incidence or severity in patients receiving CD34+ doses above prior cutoffs reported in the literature. These data do not support the routine use of graft CD34+ dose reduction.
Journal
|
CD34 (CD34 molecule)
|
CD34 positive
2ms
Comparison of cytomorphology and histomorphology in myelodysplastic syndromes. (PubMed, Front Oncol)
Histopathology provided additional diagnostic and prognostic information with high diagnostic and prognostic significance, such as fibrosis. Likewise, histopathology allowed more reliable estimation of bone marrow cellularity.
Journal
|
CD34 (CD34 molecule)
|
CD34 positive
2ms
Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF-κB inhibition and the induction of oxidative stress. (PubMed, J Cell Mol Med)
BTZ also increased mitochondrial superoxide levels in KG-1a cells, and BTZ-induced apoptosis was partially prevented by pretreatment with the antioxidant N-acetylcysteine, indicating that BTZ induces oxidative stress-mediated apoptosis in KG-1a cells. At a dosage of 0.1 mg/kg every other day for 2 weeks, BTZ significantly reduced the percentage of hCD45-positive cells in the bone marrow and peripheral blood of NSG mice engrafted with KG-1a cells with tolerable toxicity. Taken together, these data indicate that the anti-LSC potential of BTZ appears to be an important strategy for AML treatment.
Journal
|
CD123 (Interleukin 3 Receptor Subunit Alpha) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CASP3 (Caspase 3) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
CD123 positive • CD34 positive • IL3RA positive
|
bortezomib
2ms
The Correlation between VEGF and CD34 Protein Marker and Pyogenic Granuloma. (PubMed, Clin Lab)
The results suggest the role of suchbiomarkers in the oral pyogenic granuloma pathogenesis, and it appears that CD34 and VEGF are valuable biomarkers in evaluating vascular and inflammatory diseases like pyogenic granuloma.
Journal
|
VEGFA (Vascular endothelial growth factor A) • CD34 (CD34 molecule)
|
CD34 positive
3ms
Negative impact of ratio of the microvascular area to tumor area on the response to EGFR-TKI in non-small cell lung cancer with an EGFR mutation. (PubMed, J Thorac Dis)
Multivariate analysis revealed that high RMV was an independent negative predictor of PFS (hazard ratio, 3.21; 95% CI: 1.18-8.76, P=0.022). High RMV may critically affect EGFR-TKI resistance in patients with NSCLC and EGFR mutations.
Journal
|
CD34 (CD34 molecule)
|
EGFR mutation • CD34 positive
3ms
Pulmonary Epithelioid Hemangioendothelioma Requiring Differentiation from Metastatic Lung Tumor:Report of a Case (PubMed, Kyobu Geka)
When new nodules are noted on routine CT scans of other malignancies, it is essencial to make a pathological diagnosis, bearing in mind that pulmonary nodules can arise from a variety of causes.
Journal • Metastases
|
CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD34 positive
3ms
Upper abdominal pain in a young woman treated by endoscopic submucosal dissection. (PubMed, Rev Esp Enferm Dig)
Immunohistochemical analysis of the spindle cells showed CD34 was positive and CD117, S100, DOG-1, SMA, Desmin were negative. The patient was diagnosed as gastric inflammatory fibroid polyp (IFP) and no symptoms was observed in 12 months follow-up.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • ANO1 (Anoctamin 1)
|
CD34 positive
3ms
Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia. (PubMed, Blood)
Pharmacological support of PHF8 phosphorylation significantly impairs growth of primary AML patient samples. These findings provide novel opportunities for harnessing the cell-intrinsic immune response in the development of immunotherapeutic strategies against AML.
Journal • IO biomarker • Epigenetic controller
|
CD34 (CD34 molecule)
|
CD34 positive
3ms
Intramuscular Hybrid Nerve Sheath Tumor of the Thigh: Case Report and Literature Review. (PubMed, In Vivo)
Although extremely rare, HNST should be included in the extended differential diagnosis of a well-circumscribed, intramuscular soft-tissue mass in the extremities, particularly in young and early middle-aged adults.
Review • Journal
|
CD34 (CD34 molecule)
|
CD34 positive
4ms
Lipoblastoma of the lip. (PubMed, Indian J Pathol Microbiol)
Here, we report one of the first cases of lipoblastoma of lip in a 10-year-old boy with atypical immunohistochemical features and the need for thorough clinical and histopathological evaluation of cases with atypical findings. The novel pathogenetic mechanism of lipoblastoma from the cluster of differentiation 34-positive (CD34+) stem cells has also been discussed.
Journal
|
CD34 (CD34 molecule) • PLAG1 (PLAG1 Zinc Finger)
|
CD34 positive
4ms
A unique case of epithelioid sarcoma involving the mandibular alveolar mucosa. (PubMed, Oral Surg Oral Med Oral Pathol Oral Radiol)
To date, to our knowledge, only 11 instances of head and neck ES have been reported in the literature. Our case deals with the diagnosis of intraoral ES in a 55-year-old female patient, probably the first one to involve the mandibular mucosa, based on relevant clinical-radiologic-pathologic-immunohistochemical findings.
Clinical • Observational data • Retrospective data • Review • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal
|
SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • CD34 (CD34 molecule) • VIM (Vimentin)
|
CD34 positive
4ms
EXPRESS: GDF11 Level and Its Effect on Prognosis in Patients with Acute Myeloid Leukemia. (PubMed, J Investig Med)
As a conclusion increased serum GDF11 levels in AML patients may be linked to the regeneration ability of leukemic stem cells. There is a need for studies investigating GDF11 expression in myeloblasts.
Journal
|
CDH1 (Cadherin 1) • CD34 (CD34 molecule) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD34 positive
4ms
A case of superficial CD34 positive fibroblastic tumor: Diagnostic challenges and pitfalls. (PubMed, Indian J Pathol Microbiol)
A constellation of clinicoradiological profiles, IHC features, and sometimes molecular studies clinch the definitive diagnosis which can be helpful in avoiding overtreatment and chemotherapy. Here we highlight the diagnostic challenges and pitfalls in a case of SCPFT.
Journal
|
CD34 (CD34 molecule)
|
CD34 positive
4ms
Angiosarcoma of the head and neck: A clinicopathologic study with special emphasis on diagnostic pitfalls. (PubMed, Indian J Pathol Microbiol)
Head and neck AS pose a significant diagnostic challenge due to their broad morphologic spectrum. Proper clinicopathologic correlation is necessary to avoid misdiagnosis.
Journal
|
CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD34 positive
4ms
CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry. (PubMed, Genes Chromosomes Cancer)
The patient showed significant tumor response to single-agent treatment with alectinib, an ALK-tyrosine kinase inhibitor...The benefit of the early detection of CD30 expression by FCM for a prompt diagnosis and treatment is highlighted in the context of an aggressive clinical course. This case represents a learning experience regarding the need to the check the status of CD30 expression in these tumors and suggests the potential clinical benefits of CD30-targeted therapy.
Journal
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD34 (CD34 molecule) • NTRK (Neurotrophic receptor tyrosine kinase) • PLEKHH2 (Pleckstrin Homology, MyTH4 And FERM Domain Containing H2)
|
ALK rearrangement • ALK fusion • TNFRSF8 expression • CD34 positive • NTRK fusion
|
Alecensa (alectinib)
4ms
Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm. (PubMed, Virchows Arch)
Based on these findings, myeloid sarcoma/AML with RBM15::MRTFA(MKL1) fusion diagnosis was made. AML with RBM15::MRTFA(MKL1) fusion can initially present as extramedullary lesions and might cause misdiagnosis of non-hematologic malignancies.
Journal
|
CD34 (CD34 molecule) • ITGB3 (Integrin Subunit Beta 3) • MRTFA (Myocardin Related Transcription Factor A) • RBM15 (RNA Binding Motif Protein 15)
|
CD34 positive
4ms
Ultrastructural differences between synovial sarcoma and solitary fibrous tumor: comparative study in adult patients from the National Cancer Institute of Mexico. (PubMed, Ultrastruct Pathol)
Conversely, tandem junctions were not found in any SFT case. Although the presence of multivesicular buds in the SFT was not significant, it had not been previously described.
Journal
|
CD34 (CD34 molecule) • STAT6 (Signal transducer and activator of transcription 6)
|
CD34 positive
4ms
A Case of Recurrent Gastric GIST Who Survived for Long after Laparoscopic Resection and Imatinib Therapy (PubMed, Gan To Kagaku Ryoho)
The pattern of tumor recurrence noted in the present case(ie, metastasis/dissemination to the skeletal muscles)is relatively rare, and few reports have been published concerning long-term survivors through multidisciplinary treatment (surgical treatment and others). We report this case with a review of the literature.
Journal
|
CD34 (CD34 molecule)
|
KIT positive • CD34 positive
|
imatinib
5ms
Superficial CD34-Positive Fibroblastic Tumor. (PubMed, Surg Pathol Clin)
In this review, we summarize the current knowledge on this rare entity with a special focus on its clinicopathological features, morphologic spectrum, and differential diagnosis. We also provide data regarding recent discoveries on its molecular profile and discuss its prognosis and management.
Review • Journal
|
CD34 (CD34 molecule)
|
CD34 positive
5ms
GAS5 promotes cytarabine induced myelosuppression via inhibition of hematopoietic stem cell differentiation. (PubMed, Toxicol Appl Pharmacol)
In conclusion, our study highlights that GAS5 inhibited the in vitro proliferation and reduced the hematopoietic colony-forming ability of cord blood-derived CD34 cells, with the most pronounced effect observed on CFU-GEMM formation. GAS5 also enhanced the inhibitory effect of Ara-C on the in vitro hematopoietic ability of CD34 HSCs.
Journal
|
CD34 (CD34 molecule) • GATA1 (GATA Binding Protein 1) • GAS5 (Growth Arrest Specific 5)
|
CD34 positive
|
cytarabine
5ms
Journal
|
CD34 (CD34 molecule)
|
CD34 positive
5ms
Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. (PubMed, Vet Pathol)
The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization.
Preclinical • Journal • IO biomarker
|
CD34 (CD34 molecule)
|
CD34 positive
5ms
Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels. (PubMed, Cureus)
Peripheral blood mononuclear cells, bone marrow mononuclear cells, and cluster of differentiation 34-positive (CD34+) cells were isolated and assessed for the chymotrypsin-like activity of the proteasome and β5 subunit accumulation...Both parameters were shown to be associated with transfusion dependency, since transfusion-dependent patients (n=5 in each subgroup) had decreased proteasome activity and simultaneously exhibited higher ROS levels. Our results indicate that reduced β5 expression might potentially explain PIs' ineffectiveness in lower-risk MDS, elucidating the importance of the risk group in the selection of the proper treatment algorithm.
Journal
|
CD34 (CD34 molecule)
|
CD34 positive
|
bortezomib
6ms
Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors. (PubMed, Cancers (Basel))
Other drugs, such as imatinib, figitumumab, axitinib, and eribulin, are also being tested. Definitive radiotherapy appears to be a promising therapeutic modality. Since standards for the treatment of advanced and metastatic diseases are not available, further investigation of novel agents is necessary.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule) • VIM (Vimentin) • STAT6 (Signal transducer and activator of transcription 6) • CD99 (CD99 Molecule) • NAB2 (NGFI-A Binding Protein 2)
|
CD34 positive
|
imatinib • Halaven (eribulin mesylate) • Inlyta (axitinib) • figitumumab (CP-751,871)
6ms
Gastrointestinal stromal tumor in North Africa and the middle east: updates in presentation and management from an 11-year retrospective cohort. (PubMed, Hosp Pract (1995))
Imatinib was used in the neoadjuvant (18/21 patients), adjuvant (85/89 patients), and first-line metastatic treatment (28/33 patients) settings...Unlike what is usually reported, though, we did have more patients with lymphatic spread of the disease. Despite the global trend and advances in the treatment of GIST according to molecular profile, this is still far to happen in our population given the lack of access to molecular profiles and the high associated cost.
Retrospective data • Journal • Stroma
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
|
CD34 positive
|
imatinib
6ms
Diagnostic value of CD34 and CD117 Immunohistochemistry and Megakaryocyte Morphology in Myelodysplastic Syndromes: A Retrospective Case-control Study. (PubMed, Appl Immunohistochem Mol Morphol)
Although megakaryocyte counts of AML and AA were predominantly decreased, Most MDS patients (81.6%) had abnormal megakaryocyte, whereas almost none of megakaryocyte abnormality was found in AML and AA. In conclusion, combined detection of CD34 and CD117 and observation of megakaryocyte count and morphology are useful for the diagnosis of MDS.
Retrospective data • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
|
CD34 positive
7ms
Kinetics of Neoantigen Specific T Cells in Post-Transplant Relapse (ASH 2023)
Eight patients with relapsed acute leukemia after allo-SCT (7 acute myeloid leukemia and 1 acute lymphoblastic leukemia) and their transplant donors (4 matched siblings, 1 matched unrelated, 3 haploidentical) were screened for neoantigens. We analyzed samples from 7 subjects with available WES/RNAseq and detected an average of 273 somatic mutations per patient (range 108- 609) on average. Targeted next-generation sequencing was used to detect 2 somatic mutations in one subject.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Post-transplantation
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD34 (CD34 molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
TP53 mutation • PD-1 expression • HLA-A*02 • CD34 positive
7ms
Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine (ASH 2023)
Background Oral formulations ofhypomethylating agents decitabine (ASTX727) and azacitidine (cc-486, AZA) were approved respectively for treatment of higher risk myelodysplastic syndromes (HR-MDS) and for maintenance of acute myeloid leukemia after remission. We observed duration of hematological response with a length consistent with what shown in this patient subgroup, and even after a very prolonged treatment with sc-AZA. Oral AZA was generally well tolerated and AEs did not differ from those observed for sc-AZA.
Clinical
|
CD34 (CD34 molecule)
|
CD34 positive
|
Inqovi (decitabine/cedazuridine) • Onureg (azacitidine oral)
7ms
Targeting SF3B1 in High-Risk B-Cell Acute Lymphoblastic Leukemia (ASH 2023)
Plad-B treatment demonstrated in vivo therapeutic efficacy in pre-clinical B-ALL animal models. These data suggest therapeutic potential of SF3B1 inhibition in B-ALL including high-risk patients.
PARP Biomarker
|
SF3B1 (Splicing Factor 3b Subunit 1) • CD34 (CD34 molecule) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
CD34 positive
7ms
lmmunohistochemistry and digital image analysis of breast cancer associated fibroblasts' plasticity and their interactions with stromal components and clinico-pathologic parameters (ABC 2023)
Molecular subtype affects survival, invasion, and recurrence of BC tumor stroma CD34 CAFs/SMA CAFs. Tumor stroma DIA can predict BC patient’s long-term prognosis.
Stroma
|
HER-2 (Human epidermal growth factor receptor 2) • CD34 (CD34 molecule)
|
CD34 positive
7ms
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma. (PubMed, Hematol Oncol)
The present results suggest that GCD ± R may be effective and well-tolerated in Japanese patients with relapsed or refractory NHL. However, further investigation is needed to confirm these results.
P2 data • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule)
|
CD20 positive • CD34 positive
|
carboplatin • gemcitabine • Rituxan (rituximab)
7ms
Uterine Neurotrophic Tyrosine Receptor Kinase Rearranged Spindle Cell Neoplasms: Three Cases of an Emerging Entity. (PubMed, Int J Gynecol Pathol)
Two of the patients had extensive disease and underwent chemotherapy. Larotrectinib was approved for one patient who demonstrated a striking reduction in tumor volume upon initiation of this treatment.
Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CD34 (CD34 molecule) • MME (Membrane Metalloendopeptidase) • NTRK (Neurotrophic receptor tyrosine kinase) • SPECC1L (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1 Like)
|
CD34 positive
|
Vitrakvi (larotrectinib)
7ms
Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas. (PubMed, J Neurooncol)
Aberrant but exquisitely regulated EGFR can induce thrombosis in non-MVP vessels in the tumor invasion area and then promote palisading necrosis, followed by hypoxia, abnormal angiogenesis, and further tumor cell invasion.
Journal
|
EGFR (Epidermal growth factor receptor) • CD34 (CD34 molecule) • MVP (Major Vault Protein)
|
EGFR amplification • EGFR expression • EGFR wild-type • EGFR negative • CD34 positive
8ms
Precision Lineage Deconvolution in Mixed Phenotype Acute Leukemia Using Cite-Seq Derived Hematopoietic Stages Identifies Lineage Dynamics Associated with Treatment Response (ASH 2023)
Precise identification of lineage signatures in mixed phenotype leukemias shows promise in identifying clinically meaningful biological subsets of these diseases. Prospective analysis of lineage-derived biomarkers should be performed to undertake identification of formal risk stratification and treatment schemas.
IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • CD34 (CD34 molecule)
|
RUNX1 mutation • CD34 positive